Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
NCT ID: NCT02559960
Last Updated: 2021-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
20000 participants
OBSERVATIONAL
2015-09-30
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents
NCT00950612
Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents
NCT02075203
Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region
NCT00600782
BCG Revaccination Study in Diabetic and Non-Diabetic Adults
NCT06246851
Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town
NCT00460590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breviscapine Powder-Injection
Breviscapine Powder-Injection will be given to the patients, and the investigators will record all the information including ADR, application of Breviscapine Powder-Injection and the combined medications, etc.
Breviscapine Powder-Injection
Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Breviscapine Powder-Injection
Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhong Wang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhong Wang
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhong Wang, M.D.
Role: STUDY_DIRECTOR
China Academy of Chinese Medical Sciences
Xin-zhi Wang
Role: PRINCIPAL_INVESTIGATOR
The First Hospital of Henan College of Traditional Chinese Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The People's Hospital of Zuanjiang District, Chongqing City
Chongqing, Chongqing Municipality, China
Mudanjiang City Second People's Hospital
Mudanjiang, Heilongjiang, China
People's Hospital of Jun County
Hebi, Henan, China
People's Hospital of Changge City
Xuchang, Henan, China
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Zhengzhou Second Hospital
Zhengzhou, Henan, China
The First Hospital of Henan College of Traditional Chinese Medicine
Zhengzhou, Henan, China
Zaozhuang Hospital of T.C.M
Zaozhuang, Shandong, China
Shandong Energy Zaozhuang Mining Group Center Hospital
Zaozhuang, Shandong, China
Shanxi Provincial Hospital of Traditional Chinese Medicine
Taiyuan, Shanxi, China
Changzheng Hospital of Tianjin City
Tianjin, Tianjin Municipality, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
The Red Cross Hosptal of Yunnan
Kunming, Yunnan, China
First Affilicated Hospital of Kunming Medical University
Kunming, Yunnan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dengzhan-V1.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.